Five years ago, Biogen bet the company on a drug most neurologists did not believe in. Aduhelm, its controversial Alzheimer’s treatment, won accelerated FDA approval in June 2021 at a price tag that would have cost Medicare more per year than Social Security pays the average retiree. Medicare refused to cover it broadly. Biogen halved the price, then walked away entirely, discontinuing Aduhelm in January 2024. The whole episode cost the company three years of revenue growth and most of its credibility on Wall Street. What followed was a quieter, slower rebuild: new leadership, a leaner pipeline, and a genuine Alzheimer’s drug in Leqembi that actually works. The stock has responded. The filings have been more cautious.
That gap, between a share price up 65% over the past year and a business whose revenue has barely moved in half a decade, is the story right now.
The heart of it
Biogen’s filed full-year 2025 results show revenue of $9.9 billion, up just over two percent from the year before, and a net margin of 13%, meaning the company keeps about thirteen cents of profit from every dollar it collects. The stock trades at roughly 26 times last year’s earnings, our data shows, against a decade median of about 19 times. The market is paying a premium-shelf price for a business still growing at corner-store speed. The open question is whether two new drug approvals in 2026 can close that gap before the premium fades.
What the conversation is saying
The loudest claim in circulation right now comes from Simply Wall St., writing on September 27, 2026, which pegged Biogen as roughly four percent undervalued against its closing price that same day. A consensus of analysts tracked by MarketBeat as of September 24 averaged a twelve-month valuation estimate implying barely one percent upside from current levels. A Seeking Alpha piece from September 17 characterized the stock as trading at about 17.5 times forward non-GAAP earnings and described the valuation as “not expensive, but no longer cheap”, stopping short of a directional call. The consensus, in other words, is a shrug: not a disaster, not a bargain, somewhere in the middle.
That shrug deserves a harder look, because the math and the mood are pointing in different directions. The math, what the filed fundamentals actually justify, reflects a company whose revenue has shrunk or stagnated in four of the last five years. The mood, what the market is currently paying, reflects excitement about a pipeline that has not yet shown up in the income statement.
What the filings actually show
Start with the revenue line, because it tells the whole story in miniature. Biogen collected $11 billion in 2021, then watched that number fall for three straight years as its multiple sclerosis franchise aged and Aduhelm collapsed. The 2025 annual filing shows $9.9 billion, which is the first year of growth in that stretch, but growth of just over two percent. That is roughly the pace of the broader economy, not the pace of a biotech commanding a premium multiple.
The most recent quarter adds texture. Biogen’s Q2 2026 filing, covering the three months ended June 30, reported total revenue of $2.74 billion. Anti-CD20 programs, a class of drugs that suppress the immune system used mainly in MS, contributed a meaningful slice; Alzheimer’s collaboration revenue with Eisai and contract manufacturing added further layers. The core product business is the engine, but it is not accelerating.
Margins tell a similar story. The net margin has swung between roughly twelve and thirty percent over the past five years, not because the business is volatile in the way a startup is, but because one-time charges, R&D write-offs, and restructuring costs keep landing on the income statement. The 2025 margin sits near the low end of that range. R&D spending in Q2 2026 alone ran to $530 million on a GAAP basis, just under a fifth of that quarter’s revenue, which is the cost of keeping a pipeline alive.
The balance sheet deserves a sentence. As of June 30, 2026, Biogen held $1.3 billion in cash against $8.1 billion in total debt. Think of it this way: the company owes about six times what it has in the bank. The 2025 annual filing showed operating cash flow of $2.2 billion, so the debt is not unmanageable, but it does constrain how aggressively Biogen can chase new acquisitions or absorb a pipeline setback.
The pipeline argument, tested
The bull case rests on two approvals that arrived in 2026. The FDA cleared a high-dose SPINRAZA formulation in March, and in July it approved LEQEMBI IQLIK, a subcutaneous autoinjector for early Alzheimer’s. The autoinjector matters because the original Leqembi required an intravenous infusion at a clinic, which limited how many patients could realistically use it. A version a patient or caregiver can inject at home removes a real-world barrier to adoption.
Further out, Biogen is waiting on Phase 3 data for litifilimab in lupus, expected in the fourth quarter of 2026, and is developing felzartamab for kidney transplant rejection, targeting what the company describes as a $2 billion addressable market in the U.S. These are genuine opportunities. They are also, at this point, still arguments about the future, not numbers in a filing.
The Seeking Alpha piece from September 17 put the challenge plainly: Biogen needs to translate recent revenue growth “into higher margins and reduced debt.” That is the right frame. A drug approval is a catalyst; it only becomes a financial fact when patients fill prescriptions and revenue shows up in the quarterly filing.
The valuation gap
Our data shows Biogen’s price-to-earnings ratio at 25.7 times last year’s earnings, against a decade median of 18.9 times. That puts the current multiple at the 83rd percentile of its own history, meaning the stock has been cheaper than this in about eight of the last ten years. The dossier notes a trailing P/E closer to forty times when calculated against the most recent twelve months of earnings, which reflects how much the earnings-per-share line has moved around. Either way, the stock is not priced for a company whose revenue has been flat.
If earnings were to recover toward the filed trend and the multiple were to compress back toward its decade median, our data’s conditional scenario framework suggests the price would look quite different from today’s levels. We do not publish a point estimate, because the condition, margin recovery driven by new drug uptake, is genuinely uncertain. What the filed numbers do say is that the current price assumes the pipeline works, the margins expand, and the debt comes down. All three at once is a lot to assume.
Reading the numbers
- $9.9 billion, full-year 2025 revenue (10-K filed February 6, 2026): what Biogen collected from all its products and partnerships last year. It is about 10% less than the company collected in 2021, meaning four years of effort have not yet replaced what Aduhelm’s collapse took away. A household that earned $110,000 in 2021 and earns $99,000 today has the same problem: the bills are the same size, the income is not.
- 13.1%, net margin for 2025 (10-K filed February 6, 2026): the share of each revenue dollar that becomes profit after every cost is paid. Thirteen cents on the dollar is not bad for a manufacturer, but it is thin for a biotech carrying $6.3 billion in debt and a pipeline that needs constant feeding. In 2022, the same margin was 30 cents, largely because of a one-time tax benefit; the filed trend since then has been downward.
- P/E of 25.7 times, at the 83rd percentile of its own decade (our data): the price tag per dollar of last year’s profit. IF the multiple were to revert toward its decade median of 19 times AND trailing earnings were to remain near their current filed level, the arithmetic would place the price meaningfully below current levels, a scenario that depends entirely on whether pipeline-driven margin expansion materializes. The spread between 25.7 and 19 represents the market’s embedded assumption about pipeline success; whether that assumption proves warranted depends on margin and revenue outcomes not yet visible in the filings.
- $8.1 billion in total debt as of June 30, 2026 (10-Q for Q2 2026): the total amount Biogen owes lenders. Against $2.2 billion in annual operating cash flow, the company is paying off roughly one year’s worth of debt every four years at current rates, which is manageable but leaves little room for a large acquisition or an unexpected clinical failure.
For the standing yardsticks on Biogen: the price tag, the filed record, and the four gauges, refreshed with each edition, see the BullScope Evidence Sheet: Biogen.
Sources
- Biogen 10-Q, quarter ended June 30, 2026 (SEC EDGAR)
- Biogen 10-K, fiscal year ended December 31, 2025 (SEC EDGAR)
- Simply Wall St., September 27, 2026
- MarketBeat analyst consensus, September 24, 2026
- Seeking Alpha via Robinhood, September 17, 2026
- Investing.com, Biogen Q2 2026 slides, July 2026
- KFF, Aduhelm Medicare coverage analysis
- Neurology Live, Aduhelm price cut
